In pharmaceutical manufacturing, the concept of a “crisis” has evolved markedly during the past several years.
What was once considered to be an exceptional event, such as a failed batch, an isolated contamination excursion or a problematic inspection outcome, is now increasingly understood as part of the operational risk landscape that modern facilities must actively manage.
This shift reflects broader changes throughout the industry. Manufacturing networks are more complex, facilities are more flexible and regulatory expectations place greater emphasis on proactive risk management and demonstrable control.
In this environment, crisis recovery is no longer a reactive function reserved for rare emergencies. It has become a core operational capability that underpins resilience, supply continuity and regulatory confidence.
Madison Hoal (pictured), Senior Global Technical Consultant Leader at Ecolab, investigates.
When everything becomes a crisis
Today, the term “crisis” encompasses a wide spectrum of events, ranging from acute external disruptions to slower-burning compliance challenges.
Not yet a Subscriber?
This is a small extract of the full article which is available ONLY to premium content subscribers. Click below to get premium content on Manufacturing Chemist.
Subscribe now Already a subscriber? Sign in here.